SCHEMBL21982937

SCHEMBL21982937

CC(C)(C)c1cc(Cl)cc2[nH]c(=O)[nH]c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 6/20 0.42
GRIN3B O60391 6/20 0.42
GRIN1 Q05586 6/20 0.42
GRIN2A Q12879 6/20 0.42
GRIN2B Q13224 6/20 0.42
GRIN2C Q14957 6/20 0.42
GRIN3A Q8TCU5 6/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
GRIA1 P42261 3/20 0.33
CACNG8 Q8WXS5 3/20 0.33
GRM5 P41594 1/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22169013 0.76 KIF11 (0.40) GRIN1MAPT
SCHEMBL3226848 0.75 GRIN1 (0.70) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL21982934 0.73 YTHDF3 (0.35) GRIA1CACNG8
SCHEMBL3489785 0.72 GRIN2D (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL24549462 0.71 DRD2 (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29653729 0.71 DRD2 (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22928150 0.70 KIF11 (0.53) ALDH1A1KDM4EDRD2DRD4DRD3
SCHEMBL13765834 0.69 GRIA1 (0.33) GRIA1CACNG8
SCHEMBL4707291 0.68 GRIN1 (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19781547 0.64 GRIN2D (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647703-B2 Inhibitors of KRAS G12C mutant proteins ARAXES PHARMA LLC (US) 2020-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647703-B2 Inhibitors of KRAS G12C mutant proteins KRAS, NRAS, G3BP1 GRIN2D 3844/4885GRIN3B 2829/4885GRIN1 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.